Project SEREFO-NIAID (Centre de Recherche et de Formation sur VIH/Sida et Tuberculose-Institut National des Maladies Infectieuses et Allergiques)/University of Bamako Research Collaboration on HIV-TB, Bamako, Mali.
Int J Tuberc Lung Dis. 2012 Jul;16(7):911-6. doi: 10.5588/ijtld.11.0397. Epub 2012 Apr 9.
To identify strains of Mycobacterium tuberculosis complex (MTC) circulating in Bamako and to examine the relationship between the strains and their drug susceptibility profiles.
Between 2006 and 2010, we conducted a cross-sectional study using spoligotyping to identify strains of MTC recovered from 126 tuberculosis (TB) patients under treatment in Bamako, Mali.
Three members of the MTC were isolated: M. tuberculosis (71.4%), M. africanum (27.8%) and M. bovis (0.8%). Of these, three strains were found to be the most prevalent: M. tuberculosis T1 (MTB T1; 38.9%), M. africanum F2 (MAF2; 26.2%) and M. tuberculosis Latin American and Mediterranean 10 (MTB LAM 10; 10.3%). MAF2 and MTB LAM 10 strains have a lower risk of multidrug resistance (MDR) than MTB T1 (respectively OR 0.1, 95%CI 0.03-0.4 and OR 0.1, 95%CI 0.01-0.8). Age ≥ 32 years (OR 1.4, 95%CI 0.4-3.9), negative human immunodeficiency virus status (OR 0.4, 95%CI 0.1-2.5) and male sex (OR 4, 95%CI 0.9-16.5) were not associated with MDR. The prevalence of MDR among treatment and retreatment failure patients was respectively 25% and 81.8% compared to new patients (2.9%).
This study indicates a low level of primary drug resistance in Bamako, affirms the importance of using correct drug regimens, and suggests that the MTB T1 strain may be associated with the development of resistance.
鉴定在巴马科流行的结核分枝杆菌复合群(MTC)菌株,并研究这些菌株与药敏谱之间的关系。
2006 年至 2010 年,我们采用 spoligotyping 方法对马里巴马科 126 例结核病(TB)患者治疗中分离的 MTC 菌株进行了一项横断面研究。
分离出三种 MTC 成员:结核分枝杆菌(71.4%)、非洲分枝杆菌(27.8%)和牛分枝杆菌(0.8%)。其中三种菌株最为常见:结核分枝杆菌 T1(MTB T1;38.9%)、非洲分枝杆菌 F2(MAF2;26.2%)和结核分枝杆菌拉丁美洲和地中海 10 型(MTB LAM 10;10.3%)。MAF2 和 MTB LAM 10 菌株的耐多药(MDR)风险低于 MTB T1(分别为 OR 0.1,95%CI 0.03-0.4 和 OR 0.1,95%CI 0.01-0.8)。年龄≥32 岁(OR 1.4,95%CI 0.4-3.9)、人类免疫缺陷病毒(HIV)阴性(OR 0.4,95%CI 0.1-2.5)和男性(OR 4,95%CI 0.9-16.5)与 MDR 无关。治疗失败和复发失败患者的 MDR 发生率分别为 25%和 81.8%,而新患者为 2.9%。
本研究表明巴马科的初始药物耐药率较低,证实了正确使用药物方案的重要性,并提示 MTB T1 菌株可能与耐药性的发展有关。